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Summary 
TWENTY-SEVEN parenteral drug abusers had serum tested for delta antigen and antidelta 
antibody and had liver biopsies performed. All four patients with chronic active hepatitis were 
delta positive. This study suggests that delta agent infection increases the risk of progression 
of intravenous drug abuse associated liver disease to chronic active hepatitis. 
Introduction 
 Since the delta agent was first identified by Rizzetto and his colleagues in 1977 there 
has been much speculation regarding its nature and significance. The delta agent appears to be 
an RNA virus which is dependent on hepatitis B surface antigen (HBsAg) for its replication 
(Rizzetto et al, 1980). Chronic HBsAg carriers appear to be most at risk of developing delta 
infection (Smedile et al, 1981). Chronic delta infection has been shown to be associated with 
progressive liver disease (Rizzetto et al, 1977). In order to determine whether such liver 
disease was related to the delta agent per se or to the co-existant hepatitis B virus (HBV) we 
performed liver biopsies on twenty-seven parenteral drug abusers who had serum tested for 
delta antigen and antidelta antibody. We report here the histological findings in those who 
were delta positive and those who were delta negative. 
Patients and Methods 
 Twenty-seven parenteral drug abusers admitted to hospital for liver biopsy during the 
period from January 1st to August 31st 1981 are included in this study. All patients were 
referred to us from the Drug Advisory and Treatment Centre by its Medical Director, Dr. M. 
G. Kelly. 
 Patients had the following laboratory investigations performed:– full blood count, 
platelet count, prothrombin time, serum bilirubin, serum alanine and aspartate transaminase, 
alkaline phosphatase, serum proteins and albumin. Serological tests for hepatitis B virus 
included HB.Ag (RIA Ausria II Abbott), anti HBs (immunodiffusion, Shattock, 1974). 
Patients positive for HBsAg were also tested for HBs antigen and anti HB8 by semi-
microdiffusion in 0.7% agarose in barbitone buffer at pH 8.6, with double filling of wells with 
serum samples concentrated a minimum of four fold with polyacryl gel (Lypogel Hawksley) 
(Shattock, 1982). Hepatitis B core antibody (anti HBs) was also tested (RIA “Corab” Abbott 
or EIA “Corezyme” Abbott). Serum was tested for delta antigen and anti delta antibody by 
Dr. Rizzetto using his own radioimmunoassay technique (Rizzetto et al, 1979), and by 
enzymeimmunoassay in Dublin (Shattock and Morgan, 1983). 
 Liver biopsies were performed using a Menghini needle. Histological diagnosis was 
made in accordance with the criteria suggested in a Review by an International Group (1977). 
The liver histology of those with serum evidence of delta infection was compared with that of 
those without serum evidence of delta infection. 
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 Results 
 Of the twenty-seven patients studied thirteen had serological evidence of delta 
infection; fourteen did not have delta antigen or anti delta antibody. The mean age, sex and 
mean duration of intravenous abuse in both groups are tabulated in Table I. Of the thirteen 
delta positive patients twelve were HBsAg positive and one had anto HBs. Of the fourteen 
delta negative patients ten were HBsAg positive, three were HBsAg negative but had anti HBs 
and one had no marker of HBV detected in her serum. 
TABLE I 
Age, sex and duration of abuse in parenteral drug abusers. 
Patient group Number of Patients Mean age Sex Mean duration of i.v. abuse 
Delta infection 13 20.5 years 
(Range 16-27 
years) 
11 Male 
2 Female 
37.5 months (Range 24-120 
months) 
No Evidence of 
Delta infection 
14 21 years 
(Range 12-29 
years) 
11 Male 
3 Female 
32 months (Range 6-84 
months) 
 Of the thirteen delta positive patients four had chronic active hepatitis, seven had 
chronic persistent hepatitis and two had acute hepatitis. No patient in the delta negative group 
had chronic active hepatitis; eleven had chronic persistent hepatitis and three had acute 
hepatitis. These findings are summarised in Table II. 
Discussion 
 Serological evidence of delta infection was found in thirteen of 27 drug abusers tested. 
Four of these patients had evidence 
TABLE II 
Histology in delta positive and delta negative patients. 
Liver 
histology 
Delta positive 
patients 13 
Delta negative 
patients 14 
Chronic active 
hepatitis 
4 0 
Chronic persistent 
Hepatitis 
7 11 
Acute hepatitis 2 3 
of chronic active hepatitis. None of the fourteen patients without evidence of delta infection 
had histologically diagnosed chronic active hepatitis. Although the numbers involved were 
small, both groups appear comparable with regard to age, sex and duration of parenteral 
abuse. Thus delta agent infection may be associated with the progression of intravenous drug 
abuse associated liver disease to chronic active hepatitis. 
 These findings are similar to those of Rizzetto and his colleagues (1979) who 
documented the histological findings in a group of Italian non drug abusers with anti delta 
antibody in their serum. Of forty-two patients thirty-five had active liver disease which 
progressed to cirrhosis in nine and hepatoma in three. Five patients had chronic persistent 
hepatitis. In the same paper he records that of seven patients from New Jersey with anti delta 
antibody five had biopsy proven chronic active liver disease and one had chronic active liver 
disease diagnosed on the basis of a six year history of raised enzymes. Unlike the Italians, 
these patients from New Jersey were either parenteral drug abusers or haemophiliacs who 
required multiple blood transfusions. The frequency of chronic active hepatitis among 
Rizzetto’s patients was much higher than that found in either group documented in this study; 
the majority of our patients had chronic persistent hepatitis. Whilst there is a continuum of 
histological abnormality between chronic active and chronic active and chronic persistent 
hepatitis (Scheuer, 1977), the precise diagnosis usually becomes apparent on repeat biopsy six 
months after the initial biopsy. All four patients with chronic hepatitis in this study had at 
least two liver biopsies with evidence of chronic active hepatitis. 
 Parenteral drug abusers have a high risk of acquiring delta infection (Raimondo et al, 
1982) and because of decreased immunocompetence may have difficulty clearing delta 
infection in the same way as they have difficulty clearing delta infection in the same way as 
they HBsAg (Editorial, Lancet 1982). Parenteral drug abusers may thus be at increased risk of 
developing chronic active hepatitis. Whether the delta infection also increases the risk of the 
later development of hepatoma as suggested by Rizzetto el al (1979) can only be answered by 
a long term follow up study. 
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